Clinical data of COVID-19 infected patients

Objectives
This study aimed to evaluate the clinical efficacy of Paxlovid in patients hospitalized with severe/critical COVID-19.
Methods
Data were acquired from patients with severe/critical COVID-19 diagnosed between December 2022 and January 2023 at a medical center in China. Patients were divided into the Paxlovid treatment group and the conventional treatment group. The association between Paxlovid and all-cause mortality of patients during hospitalization was evaluated using the COX regression model and inverse probability weighting method, respectively. The secondary endpoint was the improvement in patients’ lung imaging findings 1 week later. The odds ratio (OR) was estimated using logistic regression.
Results
A total of 158 eligible patients were enrolled, including 50 in-hospital deaths (50/98) in the Paxlovid group and 28 (28/60) in the conventional treatment group. The corrected hazard ratio for death was 0.51 (95% CI: 0.28–0.94, p = 0.031) and the inverse probability-weight..., , , # Clinical Data of COVID-19 Infected Patients

[https://doi.org/10.5061/dryad.m63xsj49r](https://doi.org/10.5061/dryad.m63xsj49r)

the data were mainly acquired from  a large medical center in China, where the diagnosis and treatment of critical illness is one of its strengths. Clinical data was obtained by searching in the electronic medical record system. Departments included in the search were where COVID-19 cases were centralized for treatment in our center, such as the respiratory department, the isolation wards for COVID-19 cases, and the intensive care unit (ICU). Clinical data from patients diagnosed with severe or critical COVID-19 infection were continuously collected and included in this study, with a time frame ranging from December 1, 2022, to January 15, 2023, during which the Omicron infection had peaked in mainland China.

## Description of the data and file structure

The electronic medical records of patients eligible for inclusion in this hospital were analyzed, with...